Argentina Approves New 21-Valent Pneumococcal Vaccine for Adults
ANMAT Approves First 21-Valent Pneumococcal Conjugate Vaccine for Adults in Argentina
- The Argentine National Administration of Drugs, Foods and Medical Devices (ANMAT) approved the first 21-valent pneumococcal conjugate vaccine specifically developed for adults.
- The vaccine targets Streptococcus pneumoniae in individuals aged 18 years and older, addressing invasive disease and pneumonia.
In November 2026, MSD Argentina announced that ANMAT granted approval for the country’s first 21-valent polysaccharide conjugate pneumococcal vaccine tailored for adult populations. MSD Argentina is known as Merck & Co., Inc., Rahway, NJ, USA, in the United States and Canada. The immunization targets the prevention of invasive pneumococcal disease and pneumonia triggered by Streptococcus pneumoniae across adults aged 18 and older.
Geographic Variation Influences Pneumococcal Serotype Prevalence
Geographic variation heavily influences pneumococcal serotype prevalence. Regional analyses across Latin America show the necessity of interpreting local epidemiological data. Surveillance metrics from Argentina illustrate distinct age-based circulation patterns. Serotypes 12F, 3, and 14 emerged among the most prevalent across all demographic groups. Serotypes 8 and 9N demonstrated high frequency specifically within populations aged 17 and older. Among these locally monitored strains, serotypes 3, 8, 9N, and 12F find direct inclusion within the newly approved 21-valent formulation.
Phase 3 Clinical Program Data Supports Regulatory Approval
The regulatory green light relies on data derived from the extensive STRIDE Phase 3 clinical program. Key trials included STRIDE-3 (NCT05425732), which evaluated the 21-valent conjugate vaccine against PCV20 in vaccine-naive adults aged 18 and older. The STRIDE-10 (NCT05569954) trial compared the 21-valent candidate against the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in unvaccinated adults aged 50 and older. Trials STRIDE-4 (NCT05464420), STRIDE-5 (NCT05526716), STRIDE-6 (NCT05420961), and STRIDE-7 (NCT05393037) also backed the approval. Dr. Virginia Verdaguer, director of medical affairs at MSD Argentina, noted that the clinical program rigorously assessed immunogenicity and safety profiles across diverse adult cohorts, adding that the approval reflects the company’s strategy to contribute to the prevention of invasive pneumococcal disease in adults based on deep disease understanding. Dr. Sandra Lambert, associate medical director at MSD, emphasized that the vaccine covers serotypes responsible for a significant proportion of invasive adult cases, particularly among individuals aged 65 and older or those managing chronic conditions and immunocompromised states.
Theoretical Coverage Proportions in Adult Populations
According to historical national surveillance data spanning 2016 through 2023, the 21-valent formulation achieved a theoretical coverage potential of 69.8 percent among adults aged 50 to 59. For individuals aged 60 and older, the theoretical coverage reached 67 percent. Analysts emphasize that these figures reflect proportional serotype representation rather than observed clinical effectiveness.
Bacterial Infection Types Affect Adults and Children Differently
Pneumococcal disease is an infection caused by a bacterium named Streptococcus pneumoniae, with approximately 100 different serotypes capable of affecting adults differently than children. The condition can be classified as invasive or non-invasive. Non-invasive presentations include pneumonia when confined to the lungs, while invasive forms encompass pneumococcal bacteremia as an infection in the bloodstream, bacteriemic pneumococcal pneumonia featuring pneumonia with bacteremia, and pneumococcal meningitis involving infection of the membranes covering the brain and spinal cord. Pneumococcal pneumonia represents a type of bacterial pneumonia and constitutes the most common clinical presentation of the disease in adults. Sustaining epidemiological surveillance and understanding circulating serotypes allows for mapping distribution and guiding prevention strategies in adults, though vaccine usage must align with approvals from regulatory authorities, health agency recommendations, and healthcare professional judgment.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.